ATE317869T1 - Neutrales lipopolymer und liposomale zusammensetzungen daraus - Google Patents

Neutrales lipopolymer und liposomale zusammensetzungen daraus

Info

Publication number
ATE317869T1
ATE317869T1 AT00945341T AT00945341T ATE317869T1 AT E317869 T1 ATE317869 T1 AT E317869T1 AT 00945341 T AT00945341 T AT 00945341T AT 00945341 T AT00945341 T AT 00945341T AT E317869 T1 ATE317869 T1 AT E317869T1
Authority
AT
Austria
Prior art keywords
lipopolymers
liposomes
alkyl
group
substituted
Prior art date
Application number
AT00945341T
Other languages
English (en)
Inventor
Samuel Zalipsky
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE317869T1 publication Critical patent/ATE317869T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00945341T 1999-07-14 2000-07-12 Neutrales lipopolymer und liposomale zusammensetzungen daraus ATE317869T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14381099P 1999-07-14 1999-07-14

Publications (1)

Publication Number Publication Date
ATE317869T1 true ATE317869T1 (de) 2006-03-15

Family

ID=22505748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00945341T ATE317869T1 (de) 1999-07-14 2000-07-12 Neutrales lipopolymer und liposomale zusammensetzungen daraus

Country Status (24)

Country Link
US (1) US6586001B1 (de)
EP (1) EP1198490B1 (de)
JP (1) JP2003505401A (de)
KR (2) KR100758158B1 (de)
CN (1) CN1193059C (de)
AT (1) ATE317869T1 (de)
AU (1) AU769517B2 (de)
BR (1) BR0012443A (de)
CA (1) CA2379060A1 (de)
CY (1) CY1105466T1 (de)
CZ (1) CZ2002140A3 (de)
DE (1) DE60026030T2 (de)
DK (1) DK1198490T3 (de)
ES (1) ES2255501T3 (de)
HK (1) HK1048484B (de)
HU (1) HUP0202177A3 (de)
IL (2) IL147564A0 (de)
MX (1) MXPA02000402A (de)
NO (1) NO20020175L (de)
PL (1) PL352711A1 (de)
PT (1) PT1198490E (de)
RU (1) RU2250911C2 (de)
WO (1) WO2001005873A1 (de)
ZA (1) ZA200200303B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1347743T3 (da) * 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
AU2003238929A1 (en) 2002-06-07 2003-12-22 Rutgers, The State University Micelle assemblies
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
JP2006519262A (ja) * 2003-02-28 2006-08-24 アルザ・コーポレーシヨン リポソームにより誘導される補体活性化の減少のためのリポソーム組成物
CN100379404C (zh) * 2003-02-28 2008-04-09 阿尔扎公司 用于减少脂质体诱导的补体激活的脂质体组合物
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
MXPA05010926A (es) * 2003-04-15 2005-11-25 Opperbas Holding Bv Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales.
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
CA2510040C (en) * 2003-05-23 2012-01-03 Nektar Therapeutics Al, Corporation Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages
KR20060015265A (ko) * 2003-05-30 2006-02-16 알자 코포레이션 제제의 폐 투여 방법
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
NZ592917A (en) * 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
CA2542804A1 (en) * 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
US20050191344A1 (en) * 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
JP4796062B2 (ja) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド 脂質封入干渉rna
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
CA2587470A1 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusale M Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
US20070055199A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Drug delivery device for buccal and aural applications and other areas of the body difficult to access
ES2611924T3 (es) * 2006-10-03 2017-05-11 Arbutus Biopharma Corporation Formulaciones que contienen lípidos
CN101583380B (zh) * 2006-11-30 2013-07-10 尼克塔治疗公司 用于制备聚合物轭合物的方法
US8466255B2 (en) 2007-02-05 2013-06-18 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
JP5415283B2 (ja) 2007-02-07 2014-02-12 グラダリス インク. シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
US20110097720A1 (en) * 2008-01-02 2011-04-28 Alnylam Pharmaceuticals, Inc. Screening method for selected amino lipid-containing compositions
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
KR100967833B1 (ko) 2008-05-20 2010-07-05 아이디비켐(주) 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법
US9173840B2 (en) 2008-10-09 2015-11-03 Northeastern University Multifunctional self-assembling polymeric nanosystems
CN102439151A (zh) 2009-03-19 2012-05-02 默沙东公司 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制
EP2408458A1 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-schnittstellen-vermittelte unterdrückung der signal transducer and activator of transcription 6 (stat6) genexpression mit short interfering nucleic acid (sina)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害
EP2411019A2 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der signal transducer and activator of transcription 1 (stat1) gen-expression mittels sina (short interfering nucleic acid)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
EP2449114B9 (de) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Neue lipidformulierungen zur abgabe von therapiemitteln in feste tumore
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5605760B2 (ja) * 2010-01-18 2014-10-15 セイコーエプソン株式会社 吐出用液体、生体試料の吐出方法、及び化合物
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
EP2609106A4 (de) 2010-08-26 2014-03-19 Merck Sharp & Dohme Durch rna-interferenz vermittelte inhibition der prolyl-hydroxylase-domäne-2 (phd2)-genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
DK3202760T3 (da) * 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
US8846850B2 (en) 2011-02-22 2014-09-30 Rutgers, The State University Of New Jersey Amphiphilic macromolecules for nucleic acid delivery
JP5949036B2 (ja) * 2011-03-29 2016-07-06 日油株式会社 ポリオキシアルキレン修飾脂質およびその製造方法
US8575380B2 (en) 2011-10-17 2013-11-05 Nof Corporation Branched polyethylene glycol linked with diacyl glycerol, process for producing the same, and polyethylene glycol modified liposome
EP2861558B1 (de) 2012-06-15 2017-01-18 Rutgers, The State University of New Jersey Makromoleküle zur behandlung von atherosklerose
US10138203B2 (en) 2014-06-16 2018-11-27 Rutgers, The State University Of New Jersey Antibacterial agents
US9630905B2 (en) 2014-09-08 2017-04-25 Rutgers, The State University Of New Jersey Amphiphilic macromolecules and methods of use thereof
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
US10640725B2 (en) 2016-08-05 2020-05-05 Rutgers, The State University Of New Jersey Thermocleavable friction modifiers and methods thereof
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ,インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
GB202111757D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694893A1 (fr) * 1992-08-03 1994-02-25 Oreal Composition formée d'une dispersion aqueuse de vésicules de lipides amphiphiles non-ioniques stabilisées.
US5741518A (en) * 1992-08-03 1998-04-21 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
WO1995025764A1 (fr) * 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Derive bicatenaire de lipide contenant un polyoxyethylene
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
PT957929E (pt) * 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular

Also Published As

Publication number Publication date
CY1105466T1 (el) 2010-04-28
IL147564A (en) 2007-03-08
KR20020012008A (ko) 2002-02-09
HK1048484B (zh) 2005-10-14
CN1193059C (zh) 2005-03-16
US6586001B1 (en) 2003-07-01
DE60026030T2 (de) 2006-08-10
CN1360611A (zh) 2002-07-24
BR0012443A (pt) 2002-04-02
CZ2002140A3 (cs) 2002-05-15
JP2003505401A (ja) 2003-02-12
HUP0202177A3 (en) 2004-05-28
RU2250911C2 (ru) 2005-04-27
IL147564A0 (en) 2002-08-14
MXPA02000402A (es) 2002-07-30
CA2379060A1 (en) 2001-01-25
PL352711A1 (en) 2003-09-08
EP1198490B1 (de) 2006-02-15
KR20070086708A (ko) 2007-08-27
AU769517B2 (en) 2004-01-29
PT1198490E (pt) 2006-06-30
KR100758158B1 (ko) 2007-09-12
EP1198490A1 (de) 2002-04-24
HK1048484A1 (en) 2003-04-04
WO2001005873A1 (en) 2001-01-25
DK1198490T3 (da) 2006-06-19
DE60026030D1 (de) 2006-04-20
ES2255501T3 (es) 2006-07-01
HUP0202177A2 (hu) 2002-12-28
AU5930300A (en) 2001-02-05
NO20020175D0 (no) 2002-01-14
ZA200200303B (en) 2003-03-26
NO20020175L (no) 2002-01-14

Similar Documents

Publication Publication Date Title
DE60026030D1 (de) Neutrales lipopolymer und liposomale zusammensetzungen daraus
BR0016040A (pt) Composição, e, processos para aplicação de composição cosmética sobre a pele humana e para aplicação de formulação cosmética transparente sobre a pele humana
DE69917811D1 (de) Photostabile sonnenschutzmittel
AU6626698A (en) Glycerolipid compounds useful for the transfer of an active substance into a target cell
AU643282B2 (en) Liposomes with positive excess charge
DE69818042D1 (de) Flüssige benzisochinoline derivate
IL136359A0 (en) Dihydrobenzofuran derivatives and pharmaceutical compositions containing the same
DE69825626D1 (de) Heterozyklische cytotoxische wirkstoffe
TR199801229T2 (xx) ''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri
IL90543A0 (en) Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
CA2098842A1 (en) Use of host cell phospholipids for inhibiting microbial colonization
IE832001L (en) IMIDAZO £1,2-a| PYRIMIDINES.
TR200101101T2 (tr) Bilinen bradikinin antonistinin vitröz (camsı) formu.
IE802418L (en) ANTIALLERGIC AND ANTIULCER 1-OXO-1H-THIAZOLO (3,2-a)¹PYRIMIDINE-2-CARBOXAMIDES
EP0206729A3 (en) Pharmacologically active compounds
GB9624188D0 (en) Pharmaceutical formulations
DE3561948D1 (en) Oximinophosphoric acid derivatives, process for their preparation and their use as pesticides
ATE289597T1 (de) Mercapto derivate mit metallopeptidase(ace/nep) inhibiernder wirkung
MX9705136A (es) Fusacandinas antifungales.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1198490

Country of ref document: EP

REN Ceased due to non-payment of the annual fee